title: Cancer antigen 125 associated with multiple benign and malignant pathologies.
abstract: BACKGROUND
  Cancer antigen (CA) 125 tumor-associated antigen is a high molecular glycoprotein used for follow-up of epithelial ovarian cancer. The test is often requested as a differential diagnosis in patients with pleural or peritoneal fluid. This study analyzes the prevalence of CA-125 increases in a population of patients attending a general hospital and discusses the possible clinical implications of increased levels.
  
  
  METHODS
  On 4 different days, 380 CA-125 assays were performed in randomly selected patients attending our hospital. Serum CA-125 was measured with a commercial enzyme immunoassay, and clinical records were reviewed for assessment of clinical parameters.
  
  
  RESULTS
  Sixty-one patients (16%) had increased CA-125. The pathologies of these patients were heart failure in 9 (14.7%), lung disease 11 (18%), hepatic cirrhosis in 7 (11.4%), malignant tumors in 9 (14.7%), intra-abdominal nonhepatic disease in 6 (10%), previous surgery in 17 (27.8%), and miscellaneous in 2 (3%). Effusions were seen in 34 patients (55.7%).
  
  
  CONCLUSIONS
  Our data confirm the variety of benign and malignant pathologies coursing with increased CA-125. Cardiovascular and chronic liver disease were the most frequent diagnoses in patients with increased CA-125; this supports the opinion that CA-125 lacks utility as a marker for malignancy. CA-125 could have a role in the follow-up of cardiovascular, hepatic, and tumoral diseases with serosal involvement.
authors.affiliation: Servicio de Oncología, Clínica Puerta de Hierro, Hospital Universitario, Madrid, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Miralles
authors.forename: M
authors.initials: M
authors.lastname: Orea
authors.forename: P
authors.initials: P
authors.lastname: España
authors.forename: M
authors.initials: M
authors.lastname: Provencio
authors.forename: A
authors.initials: A
authors.lastname: Sánchez
authors.forename: B
authors.initials: B
authors.lastname: Cantos
authors.forename: R
authors.initials: R
authors.lastname: Cubedo
authors.forename: E
authors.initials: E
authors.lastname: Carcereny
authors.forename: F
authors.initials: F
authors.lastname: Bonilla
authors.forename: T
authors.initials: T
authors.lastname: Gea
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001201:Ascites / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood; D010996:Pleural Effusion / Q000097:blood*; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen